Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Patent Act

Version of the schedule from 2015-06-17 to 2024-11-11:


SCHEDULE 1(Definition “pharmaceutical product” in section 21.02 and paragraph 21.03(1)(a))

abacavir (ABC)tablet, 300 mg (as sulfate); oral solution, 100 mg (as sulfate)/5 mL
abacavir + lamivudine + zidovudinetablet, 300 mg (as sulfate) + 150 mg + 300 mg
aciclovirtablet, 200 mg; powder for injection, 250 mg (as sodium salt) in vial
amphotericin Bpowder for injection, 50 mg in vial
amprenavirtablet, 150 mg; capsule, 50 mg or 150 mg; oral solution, 15 mg/mL
azithromycincapsule, 250 mg or 500 mg; suspension, 200 mg/5 mL
beclometasoneinhalation (aerosol), 50 micrograms per dose (dipropionate) or 250 micrograms (dipropionate) per dose
ceftazidimepowder for injection, 250 mg (as pentahydrate) in vial
ceftriaxoneinjection, 500 mg (as sodium); powder for injection, 250 mg (as sodium salt) in vial
ciclosporincapsule, 25 mg; concentrate for injection, 50 mg/mL in 1-mL ampoule (for organ transplantation)
ciprofloxacintablet, 250 mg (as hydrochloride)
ciprofloxacintablet, 250 mg or 500 mg
daunorubicinpowder for injection, 50 mg (as hydrochloride) in vial
delavirdinecapsule or tablet, 100 mg (as mesylate)
didanosine (ddI)buffered chewable, dispersible tablet, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg; buffered powder for oral solution, 100 mg, 167 mg, 250 mg, packets; unbuffered enteric coated capsule, 125 mg, 200 mg, 250 mg, 400 mg
diphtheria antitoxininjection, 10 000 IU or 20 000 IU in vial
diphtheria vaccine
doxorubicinpowder for injection, 10 mg or 50 mg (hydrochloride) in vial
efavirenz (EFV or EFZ)capsule, 50 mg, 100 mg or 200 mg; oral solution, 150 mg/5 mL
efavirenz + emtricitabine + tenofovir disoproxiltablet, 600 mg + 200 mg + 300 mg
eflornithineinjection, 200 mg (hydrochloride)/mL in 100-mL bottles
emtricitabine + tenofovir disoproxiltablet, 200 mg + 300 mg
enalapriltablet, 2.5 mg
erythromycincapsule or tablet, 250 mg (as stearate or ethyl succinate); powder for oral suspension, 125 mg (as stearate or ethyl succinate); powder for injection, 500 mg (as lactobionate) in vial
etoposidecapsule, 100 mg; injection, 20 mg/mL in 5-mL ampoule
factor IX (complex coagulation factors II, VII, IX, X) concentratedried
hepatitis B vaccine
ibuprofentablet, 200 mg or 400 mg
indinavir (IDV)capsule, 200 mg, 333 mg or 400 mg (as sulfate)
insulin injection (soluble)injection, 40 IU/mL in 10-mL vial or 100 IU/mL in 10-mL vial
intermediate-acting insulininjection, 40 IU/mL in 10-mL vial; 100 IU/mL in 10-mL vial (as compound insulin zinc suspension or isophane insulin)
isoniazid + pyrazinamide + rifampintablet, 50 mg + 300 mg + 120 mg
ivermectinscored tablet, 3 mg or 6 mg
lamivudine (3TC)capsule or tablet, 150 mg; oral solution 50 mg/5 mL
lamivudine + nevirapine + zidovudinetablet, 150 mg + 200 mg + 300 mg
lamivudine + zidovudinetablet, 150 mg + 300 mg
levodopa + carbidopatablet, 100 mg + 10 mg or 250 mg + 25 mg
levofloxacintablet, 250 mg or 500 mg
lithium carbonatecapsule or tablet, 300 mg
lopinavir + ritonavir (LPV/r)capsule, 133.3 mg + 33.3 mg; oral solution, 400 mg + 100 mg/5 mL
metoclopramidetablet, 10 mg (hydrochloride); injection, 5 mg (hydrochloride)/mL in 2-mL ampoule
metronidazoletablet, 250 mg or 500 mg; injection, 500 mg in 100-mL vial; suppository, 500 mg or 1 g; oral suspension, 200 mg (as benzoate)/5 mL
morphineinjection, 10 mg in 1-mL ampoule (sulfate or hydrochloride); oral solution, 10 mg (hydrochloride or sulfate)/5 mL; tablet, 10 mg (sulfate)
nelfinavir (NFV)tablet, 250 mg (as mesilate); oral powder, 50 mg/g
nevirapine (NVP)tablet, 200 mg; oral suspension, 50 mg/5 mL
nifedipinesustained release formulations, tablet, 10 mg
nitrofurantointablet, 100 mg
ofloxacintablet, 200 mg or 400 mg
oseltamivir phosphatecapsule, 75 mg; powder for oral suspension, 12 mg/mL
potassium chloridepowder for solution
ranitidinetablet, 150 mg (as hydrochloride); oral solution, 75 mg/5 mL; injection, 25 mg/mL in 2-mL ampoule
ritonavircapsule, 100 mg; oral solution, 400 mg/5 mL
salbutamoltablet, 2 mg or 4 mg (as sulfate); inhalation (aerosol), 100 micrograms (as sulfate) per dose; syrup, 2 mg/5 mL; injection, 50 micrograms (as sulfate)/mL in 5-mL ampoule; respirator solution for use in nebulizers, 5 mg (as sulfate)/mL
saquinavir (SQV)capsule, 200 mg
stavudine (d4T)capsule, 15 mg, 20 mg, 30 mg or 40 mg; powder for oral solution, 5 mg/5 mL
tenofovir disoproxiltablet, 300 mg
testosteroneinjection, 200 mg (enantate) in 1-mL ampoule
timololsolution (eye drops), 0.25% or 0.5% (as maleate)
verapamiltablet, 40 mg or 80 mg (hydrochloride); injection, 2.5 mg (hydrochloride)/mL in 2-mL ampoule
zalcitabinecapsule or tablet, 0.375 mg or 0.750 mg
zidovudine (ZDV or AZT)tablet, 300 mg; capsule, 100 mg or 250 mg; oral solution or syrup, 50 mg/5 mL; solution for IV infusion injection, 10 mg/mL in 20-mL vial
  • 2004, c. 23, Sch. 1
  • SOR/2005-276
  • SOR/2006-204
  • SOR/2015-154

Date modified: